By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





Company News
Intarcia Therapeutics, Inc. Release: Chairman & CEO Kurt Graves Presents First "Key Disruptor Award" To Tom Alessi, Ph.D., For His Innovations In Chemistry And Manufacturing That Transform Medicines For Patients 6/19/2014 10:02:27 AM
Intarcia Therapeutics, Inc.'s Once-A-Year Diabetes Drug ITCA 650 Impresses In Phase 3 Trial 6/16/2014 7:06:24 AM
Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American Diabetes Association Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar In Patients With Very Poorly Controlled Diabetes 6/16/2014 6:29:50 AM
Boston-Based Intarcia Therapeutics, Inc. Grabs $200 Million To Beef Up Pipeline 4/1/2014 7:24:14 AM
Intarcia Therapeutics, Inc. CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan 1/13/2014 8:41:33 AM
Intarcia Therapeutics, Inc. Appoints Nancy Thornberry To Board Of Directors 12/3/2013 8:05:10 AM
Intarcia Therapeutics, Inc. Appoints Raymond Keane Vice President, General Counsel, and Chief Legal Officer 9/9/2013 8:36:10 AM
Intarcia Therapeutics, Inc. Appoints Gino Santini to Its Board of Directors 7/26/2013 9:39:02 AM
Intarcia Therapeutics, Inc. Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs 7/17/2013 7:19:34 AM
Intarcia Therapeutics, Inc. Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies 6/13/2013 3:06:40 PM
12345
//-->